2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMOPending
Objective: -To investigate the effects of recombinant human erythropoietin (rHu-EPO) on myocardial perfusion and efficiency in patients with CHF using positron emission tomography (PET) and cardiac magnetic resonance (CMR).Secondary objectives: -To…